AR046765A1 - Prolinilarilacetamidas - Google Patents
ProlinilarilacetamidasInfo
- Publication number
- AR046765A1 AR046765A1 ARP040104656A ARP040104656A AR046765A1 AR 046765 A1 AR046765 A1 AR 046765A1 AR P040104656 A ARP040104656 A AR P040104656A AR P040104656 A ARP040104656 A AR P040104656A AR 046765 A1 AR046765 A1 AR 046765A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- mono
- coor3
- coo
- unsubstituted
- Prior art date
Links
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 COOA Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10358814A DE10358814A1 (de) | 2003-12-16 | 2003-12-16 | Prolinylarylacetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046765A1 true AR046765A1 (es) | 2005-12-21 |
Family
ID=34683363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104656A AR046765A1 (es) | 2003-12-16 | 2004-12-15 | Prolinilarilacetamidas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7732481B2 (https=) |
| EP (1) | EP1697318B1 (https=) |
| JP (1) | JP4800969B2 (https=) |
| KR (1) | KR20060113729A (https=) |
| CN (1) | CN1894210A (https=) |
| AR (1) | AR046765A1 (https=) |
| AT (1) | ATE406350T1 (https=) |
| AU (1) | AU2004299197B2 (https=) |
| BR (1) | BRPI0417630A (https=) |
| CA (1) | CA2549589A1 (https=) |
| DE (2) | DE10358814A1 (https=) |
| ES (1) | ES2310772T3 (https=) |
| MX (1) | MXPA06006740A (https=) |
| RU (1) | RU2006125509A (https=) |
| WO (1) | WO2005058817A1 (https=) |
| ZA (1) | ZA200605841B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1818330A1 (de) | 2006-02-14 | 2007-08-15 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| MY146623A (en) | 2006-05-16 | 2012-09-14 | Boehringer Ingelheim Int | Substituted prolinamides, manufacturing, and the use thereof as medicaments |
| WO2009000878A1 (en) * | 2007-06-28 | 2008-12-31 | Novartis Ag | Kallikrein 7 modulators |
| WO2011027888A1 (ja) * | 2009-09-07 | 2011-03-10 | 大日本住友製薬株式会社 | ジアミド－フェニル誘導体、またはその薬学的に許容される塩 |
| CN109761957B (zh) * | 2019-01-18 | 2020-05-19 | 西安交通大学 | 一种含有羟脯氨酸的化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| BRPI0408444A (pt) * | 2003-04-03 | 2006-04-04 | Merck Patent Gmbh | derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose |
| PL377633A1 (pl) * | 2003-04-03 | 2006-02-06 | Merck Patent Gmbh | Związki karbonylowe |
| DE102004014945A1 (de) * | 2004-03-26 | 2005-10-13 | Merck Patent Gmbh | Prolinylderivate |
-
2003
- 2003-12-16 DE DE10358814A patent/DE10358814A1/de not_active Withdrawn
-
2004
- 2004-11-26 AU AU2004299197A patent/AU2004299197B2/en not_active Ceased
- 2004-11-26 RU RU2006125509/04A patent/RU2006125509A/ru not_active Application Discontinuation
- 2004-11-26 US US10/583,094 patent/US7732481B2/en not_active Expired - Fee Related
- 2004-11-26 AT AT04820404T patent/ATE406350T1/de not_active IP Right Cessation
- 2004-11-26 JP JP2006544256A patent/JP4800969B2/ja not_active Expired - Fee Related
- 2004-11-26 MX MXPA06006740A patent/MXPA06006740A/es not_active Application Discontinuation
- 2004-11-26 KR KR1020067011704A patent/KR20060113729A/ko not_active Withdrawn
- 2004-11-26 WO PCT/EP2004/013509 patent/WO2005058817A1/de not_active Ceased
- 2004-11-26 CN CNA2004800376989A patent/CN1894210A/zh active Pending
- 2004-11-26 CA CA002549589A patent/CA2549589A1/en not_active Abandoned
- 2004-11-26 BR BRPI0417630-8A patent/BRPI0417630A/pt not_active Application Discontinuation
- 2004-11-26 ES ES04820404T patent/ES2310772T3/es not_active Expired - Lifetime
- 2004-11-26 DE DE502004007959T patent/DE502004007959D1/de not_active Expired - Lifetime
- 2004-11-26 EP EP04820404A patent/EP1697318B1/de not_active Expired - Lifetime
- 2004-12-15 AR ARP040104656A patent/AR046765A1/es unknown
-
2006
- 2006-07-14 ZA ZA200605841A patent/ZA200605841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060113729A (ko) | 2006-11-02 |
| DE502004007959D1 (de) | 2008-10-09 |
| ZA200605841B (en) | 2007-10-31 |
| US7732481B2 (en) | 2010-06-08 |
| DE10358814A1 (de) | 2005-07-21 |
| JP4800969B2 (ja) | 2011-10-26 |
| CN1894210A (zh) | 2007-01-10 |
| AU2004299197B2 (en) | 2010-08-05 |
| EP1697318B1 (de) | 2008-08-27 |
| MXPA06006740A (es) | 2006-08-18 |
| US20070185189A1 (en) | 2007-08-09 |
| WO2005058817A1 (de) | 2005-06-30 |
| ATE406350T1 (de) | 2008-09-15 |
| JP2007513988A (ja) | 2007-05-31 |
| EP1697318A1 (de) | 2006-09-06 |
| RU2006125509A (ru) | 2008-01-27 |
| CA2549589A1 (en) | 2005-06-30 |
| ES2310772T3 (es) | 2009-01-16 |
| BRPI0417630A (pt) | 2007-03-27 |
| AU2004299197A1 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043833A1 (es) | Derivados de 1,2 diazol. metodo de preparacion y composiciones farmaceuticas | |
| AR044818A1 (es) | Acidos pirrolidin 1-2 dicarboxilicos-1-[4-(etinil-fenil)amida]-2-[(fenil)-amido] derivados y procedimiento para preparar dichos compuestos | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| UY28423A1 (es) | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| EA200870127A1 (ru) | Полициклические производные аминокислот и способы их применения | |
| PE20130152A1 (es) | Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b | |
| PE20040197A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
| CR7496A (es) | Piridinoilpiperidinas como agonistas de 5- ht1f | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| PE20110568A1 (es) | Agentes terapeuticos 414 | |
| AR037972A1 (es) | Pirrolopirimidinas | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| PE20080074A1 (es) | Derivados de amida como agentes inhibidores de la quinasa c-fms | |
| AR037418A1 (es) | Derivados de benzotiazol | |
| AR046643A1 (es) | Derivados de pirrol | |
| ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| AR045733A1 (es) | Derivados de aminobencimidazol | |
| UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
| SE0302324D0 (sv) | Novel compounds | |
| SE0302323D0 (sv) | Novel compounds | |
| SE0403171D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |